생명과학회지 (Journal of Life Science)

  • 제21권12호
  • /
  • Pages.1778-1783
  • /
  • 2011
  • /
  • 1225-9918(pISSN)
  • /
  • 2287-3406(eISSN)
한국생명과학회 (Korean Society of Life Science)
권호 표지
DOI QR코드

DOI QR Code

G-CSF 단백질 N-말단의 비 알파-Helix 영역의 돌연변이에 의한 분비 조절

Modulation of G-CSF Secretion by Mutations of Non Alpha-Helical Region in N-Terminus

  • 박정혜 (동의대학교 임상병리학과) ;
  • 박정애 (동의대학교 임상병리학과) ;
  • 강석우 (국립농업과학원 농업생물부) ;
  • 구태원 (국립농업과학원 농업생물부) ;
  • 정경태 (동의대학교 임상병리학과)
  • Park, Jeong-Hae (Department of Clinical Laboratory Science, Dong Eui University) ;
  • Park, Jung-Ae (Department of Clinical Laboratory Science, Dong Eui University) ;
  • Kang, Seok-Woo (Department of Agricultural Biology, National Academy of Agricultural Science, RDA) ;
  • Goo, Tae-Won (Department of Agricultural Biology, National Academy of Agricultural Science, RDA) ;
  • Chung, Kyung-Tae (Department of Clinical Laboratory Science, Dong Eui University)
  • 투고 : 2011.11.20
  • 심사 : 2011.12.21
  • 발행 : 2011.12.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

조혈에 관여하는 cytokine은 골수세포의 성장과 분화를 촉진시켜 혈구세포 생산을 조절한다. 이런 cytokine을 조혈성장인자(hematopoitic growth factor)이라고 하고, 그 중에서 호중구 세포(neutrophil) 성장에 관여하는 과립구 콜로니 자극 인자(granulocyte-colony stimulating factor, G-CSF)는 임상적 치료제로서 아주 중요하다. 왜냐하면 화학적 항암치료를 받는 환자들에게 심각한 호중구 세포가 감소하는 증세(neutropenia)가 발생하여 감염으로 인한 사망이 일어나기 때문이다. 두 종류의 G-CSF 재조합 단백질이 치료제로 승인 받아 사용되고 있으며, G-CSF 재조합 단백질 생산에 대한 연구가 지속적으로 이루어지고 있다. 선행연구에서 본 연구팀은 누에에서 유래된 Bm5 세포주에서 G-CSF의 생산을 증대하기 위해 누에 prophenoloxidase activating enzyme의 Endoplasmic reticulum targeting signal sequence유전자와 사람 G-CSF 유전자를 융합한 chimera 유전자를 제작하여 재조합 G-CSF 단백질을 생산하였다. 본 연구에서는 이 chimera 유전자가 생산하는 재조합 G-CSF 단백질의 N-말단에 3 개의 아미노산이 결여되는 3 종류의 돌연변이 유전자를 제작하여 G-CSF 단백질 생산에 미치는 영향을 조사하였다. 그 중 한 돌연변이 유전자에 의해 세포 밖으로 분비된 G-CSF 단백질의 생산이 현저히 감소하여, N-말단 부분이 이 단백질의 분비에 관여한다는 것을 알 수 있었다.

Hematopoietic cytokines regulate production of blood cells by stimulating proliferation and differentiation of bone marrow cells. Among these hematopoietic cytokines, called hematopoitic growth factors, glranulocyte-colony stimulating Factor (G-CSF), which regulates growth of neutrophils, is one of important therapeutic factors because cancer patients suffer with neutropenia which is severe reduction of neutrophils after chemotherapy. Two groups of recombinant G-CSF have approved and used for therapeutic purposes and many researches are still on-going to produce recombinant G-CSF by different techniques. We engineered human G-CSF with Bombyx specific endoplasmic reticulum (ER) signal sequence, therefore, secretion of human G-CSF protein was improved in Bombyx mori-origined cell line, Bm5. The Bombyx ER signal sequence and human G-CSF matured protein region chimera was further remodeled at the N-terminus of matured G-CSF protein to understand roles of N-terminus on outer cellular secretion and/or production. Three different mutants were generated deleting three amino acids in non alpha-helical region in N-terminus in order to scan important amino acids for G-CSF secretion. One of 3 different N-terminal deletion mutants showed dramatically reduction of secreted amount of G-CSF indicating its important role on secretion. The data suggest that remodeling in non alpha-helical region of N-terminus is also important for recombinant G-CSF production.

키워드

참고문헌

  1. Alberts, B., A. Johnson, J. Lewis, M. Raff, K. Roberts, and P. Walter. 2007. The Molecular Biology of the Cell. Chapter 12. pp. 723-745, Garland Science. New York, NY. USA.
  2. Carter, D., R. Keeble, and R. Thorpe. 2004. Human serum inactivates non-glycosylated but not glycosylated granulocyte colony stimulating factor by a protease dependent mechanism: significance of carbohydrates on the glycosylated molecule. Biologicals 32, 37-47. https://doi.org/10.1016/j.biologicals.2003.12.002
  3. Carter, R., M. Whitmore, and R. Thorpe. 2004. The significance of carbohydrates on G-CSF: differential sensitivity of G-CSFs to human neutrophil elastase degradation. J. Leukoc. Biol. 75, 515-522. https://doi.org/10.1189/jlb.0803378
  4. Cowling, G. and T. Dexter. 1992. Erythropoietin and myeloid colony stimulating factors. Trends Biotechnol. 10, 349-357. https://doi.org/10.1016/0167-7799(92)90267-Y
  5. Herrmann, F., A. Lindemann, and R. Mertelsmann. 1990. G-CSF and M-CSF: from molecular biology to clinical application. Biotherapy 2, 315-324. https://doi.org/10.1007/BF02170081
  6. Hill, P., D. Osslund, and D. Eisenberg. 1993. The structure of granulocyte-colony-stimulating factor and its relationship to other growth factors. Proc. Natl. Acad. Sci. USA 90, 5167-5171. https://doi.org/10.1073/pnas.90.11.5167
  7. Hoglund, M. 1998. Glycosylated and non-glycosylated recombinant human granulocyte colony-stimulating factor (rhG-CSF)-what is the difference? Med. Oncol. 15, 229-233. https://doi.org/10.1007/BF02787205
  8. Hubel, K., C. Dale, A. Engart, and W. Liles. 2000. Use of G-CSF for granulocyte transfusion therapy. Cytokines Cell Mol. Ther. 6, 89-95. https://doi.org/10.1080/13684730050515813
  9. Kuderer, N., D. Dale, J. Crawford, L. Cosler, and G. Lyman. 2006. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106, 2258-2266. https://doi.org/10.1002/cncr.21847
  10. Lu, S., L. Clogston, O. Narhi, A. Merewether, R. Pearl, and C. Boone. 1992. Folding and oxidation of recombinant human granulocyte colony stimulating factor produced in Escherichia coli. Characterization of the disulfide-reduced intermediates and cysteine-serine analogs. J. Biol. Chem. 267, 8770-8777.
  11. Martin-Christin, F. 2001. Granulocyte colony stimulating factors: how different are they? How to make a decision? Anticancer Drugs 12, 185-191. https://doi.org/10.1097/00001813-200103000-00002
  12. Nagata, S., M. Tsuchiya, S. Asano, Y. Kaziro, T. Yamazaki, O. Yamamoto, Y. Hirata, N. Kubota, M. Oheda, and H. Nomura. 1986. Molecular cloning and expression of cDNA for human granulocyte colony-stimulating factor. Nature 319, 415-418. https://doi.org/10.1038/319415a0
  13. Nicola, N. and D. Metcalf. 1985. The colony-stimulating factors and myeloid leukemia. Cancer Surv. 4, 789-815.
  14. Nissen, C. 1994. Glycosylation of recombinant human granulocyte colony stimulating factor: implications for stability and potency. Eur. J. Cancer 30A, S12-14.
  15. Oh-eda, M., M. Hasegawa, K. Hattori, H. Kuboniwa, T. Kojima, T. Orita, K. Tomonou, T. Yamazaki, and N. Ochi. 1990. Granulocyte colony-stimulating factor protects it against polymerization and denaturation allowing It to Retain Its Biological Activity. J. Biol. Chem. 265, 11432-11435.
  16. Park, J., H. Jang, S. Kang, T. Goo, and K. Chung. 2010. Expression and production of human granulocyte colony stimulating factor (G-CSF) in Silkworm cell line. J. Life Sci. 20, 1569-1741. https://doi.org/10.5352/JLS.2010.20.11.1577
  17. Price, T. 2002. Granulocyte transfusion in the G-CSF era. Int. J. Hematol. 76, 77-80. https://doi.org/10.1007/BF03165092
  18. Scrip Report. 2007. Biosimilar, Biogenerics and Follow-on Biologics. Informa UK Ltd. (http://www.scripintelligence.com/ multimedia/archive/00000/BS1342_117a.pdf).
  19. Souza, L., T. Boone, J. Gabrilove, P. Lai, K. Zsebo, D. Murdock, V. Chazin, J. Bruszewski, H. Lu, K. Chen, J. Barendt, E. Platzer, M. Moore, R. Mertelsmann, and K. Welte. 1986. Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells. Science 232, 61-65. https://doi.org/10.1126/science.2420009
  20. Spiekermann, K., J. Roesler, A. Emmendoerffer, J. Elsner, and K. Welte. 1997. Functional features of neutrophils induced by G-CSF and GM-CSF treatment: differential effects and clinical implications. Leukemia 11, 466-478. https://doi.org/10.1038/sj.leu.2400607
  21. Tamada, T., E. Honjo, Y. Maeda, T. Okamoto, M. Ishibashi, M. Tokunaga, and R. Kuroki. 2006. Homodimeric cross-over structure of the human granulocyte colony-stimulating factor (GCSF) receptor signaling complex. Proc. Natl. Acad. Sci. USA 28, 3135-3140.
  22. Vanz, S., G. Rnard, S. Palma, M. Chies, L. Dalmora, A. Basso, and S. Santos. 2008. Human granulocyte colony stimulating factor (hG-CSF): cloning, overexpression, purification and characterization. Microbial. Cell Factories 7, 13. https://doi.org/10.1186/1475-2859-7-13
  23. Visani, G. and S. Manfroi. 1995. G-CSF in the biology and treatment of acute myeloid leukemias. Leuk. Lymphoma. 18, 423-428. https://doi.org/10.3109/10428199509059640
  24. Zhang, J., N. Kalogerakis, L. Behie, and K. Iatrou. 1992. Investigation of reduced serum and serum-free media for the cultivation of insect cells (Bm5) and the production of baculovirus (BmNPV). Biotechnol. Bioeng. 40, 1165-1172. https://doi.org/10.1002/bit.260401005
  25. Zink, T., A. Ross, K. Lüers, C. Cieslar, R. Rudolph, and A. Holak. 1994. Structure and dynamics of the human granulocyte colony-stimulating factor determined by NMR spectroscopy. Loop mobility in a four-helix-bundle protein. Biochemistry 33, 8453-8463. https://doi.org/10.1021/bi00194a009